Introduction 55
Entamoeba histolytica is a parasitic amoeba which infects an estimated 50 million 56 people worldwide, resulting in around 70,000 deaths per year [1] . E. histolytica infection is 57 known as amoebiasis and primarily affects the intestinal tract in humans, most commonly 58 causing symptoms such as abdominal pain, bloody diarrhea, and colitis. In rare cases the 59 infection spreads to other organs such as the liver and brain, and in serious cases results in 60 patient death [2] . E. histolytica's life cycle consists of a trophozoite vegetative stage which 61 matures in its host to an infective cyst stage. The cyst stage is excreted in the host's feces, 62 infecting a new host when ingested via a route such as drinking contaminated water. Due to this 63 mode of transmission E. histolytica disproportionately affects populations experiencing 64 sanitation problems associated with low socioeconomic status [2] [3] [4] . Malnutrition is also known 65 to be a major risk factor for amoebiasis, especially in children [5] . In the majority of cases where 66 E. histolytica is ingested it lives asymptomatically in the human host's intestinal tract. Symptoms 67 develop when compromise of the mucosal layer allows it to come into contact with the intestinal 68 wall, at which point it invades the wall and surrounding tissue causing characteristic 'flask-69 shaped ulcers' [6] .
70
E. histolytica infection is currently treated with the 5-nitroimidazole drug metronidazole, 71 which has been in use since the 1960s and experiences widespread use as a treatment against 72 anaerobic microbial infections. However, while successful, metronidazole is not a perfect 73 treatment against E. histolytica, with a few particularly notable existing issues. One of these is 74 problems with lack of patient compliance with the course of treatment, leading to relapses and 75 increased disease spread [7] . This is possibly due to factors such as drug adverse effects or the 
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The antimalarial mefloquine is a 4-methanolquinoline compound structurally more 85 related to quinine than chloroquine. Like metronidazole, mefloquine is a successful and widely-86 used antiparasitic drug. In addition to its effectiveness against Plasmodium falciparum and P.
87
vivax mefloquine has been shown over the years to possess in vitro or in vivo activity against 88 Trypanosoma, Schistosoma, Echinococcosis, and Babesia species [14] [15] [16] [17] [18] . As well as its 89 effects on blood-stage malaria parasites, mefloquine is known for its ability to cross the blood-90 brain barrier, resulting in neuropsychiatric adverse events in some patients [19, 20] . Other 91 notable pharmacokinetic attributes of mefloquine include a relatively long half-life and only 92 partial absorption in the intestines, resulting in a profile potentially useful for persistent, invasive 93 infections with a reservoir of parasites in the lumen [21, 22] .
94
Based on these factors we decided to examine mefloquine for activity against E. Trypan blue exclusion cell viability assay 128 E. histolytica trophozoites were seeded into 96-well plates at 5,000 cells/well and treated 129 in triplicates with two-fold serially-diluted mefloquine ranging from 6.25 to 0.10 μM. Cells were 130 incubated for 24 hr, then 10 µL of cells from each desired well were combined with 10 µl of 131 trypan blue and the resulting mixture was counted with a hemocytometer.
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Determination of anti-amoebic drug effectiveness in vitro over time 134 Effects of mefloquine and metronidazole on E. histolytica trophozoite cell viability were 135 determined as described in a previous section at a series of timepoints ranging from 0.5 to 46 136 hours following drug administration. EC 50 values were calculated at each timepoint as previously 137 described.
138 139
Microscopic observation of drug effects on cell morphology
140 Confluent E. histolytica trophozoites were treated with 4 μM of mefloquine in 50 mL 141 culture flasks and observed over the course of 6 hours using brightfield microscopy (Zeiss).
142
Representative images demonstrating cellular morphology were captured at 1-hour intervals 143 from the beginning to the end of the experiment. These results suggest that the mechanism by which mefloquine kills E. histolytica trophozoites 235 is inherently more rapid than that of metronidazole. to the control (Figure 5) , indicating that the drug is effectively killing the cysts. In contrast, 258 metronidazole up to 20 µM had no effect [ Figure 5 ]. 
Discussion

268
In this study the FDA-approved antimalarial drug mefloquine was shown to kill E.
269
histolytica trophozoites in vitro more potently and rapidly than the current standard therapy, 
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The first concern with metronidazole therapy is patient noncompliance due to both 280 adverse effects and the requirement for dosage past symptom improvement. Reported 281 noncompliance has been linked with increased recurrence and prevalence of the disease and 282 has been shown to be increased in populations known to be at greater risk for infection [8] . We 283 found that mefloquine achieves its amoebicidal effects in vitro much more rapidly than 284 metronidazole, a favorable characteristic which could result in much shorter and hence less 285 onerous clinical dosing schedules, which in turn could partially alleviate patient noncompliance.
286
Regarding dosage, we found a concentration of 3 µM to kill nearly 100% of E. histolytica 287 trophozoites after 48 hours. Mefloquine is currently prescribed in doses of 1250 mg for cases of 288 acute malaria, and previous studies have shown lower doses than this to be capable of 289 producing plasma C max values above the 3 µM level [21] . Additionally, the half-life of mefloquine 290 has been shown to be up to 12 days, in contrast to a reported value of only 8 hours for 291 metronidazole [21, 25] . All of this points to the idea that one or a small number of doses could 292 potentially produce the desired therapeutic effects in humans that currently require many more 293 doses of metronidazole.
294
The second concern is the inability of metronidazole to kill or prevent development of the 295 infective cyst stage of Entamoeba. Due to its extremely high intestinal absorption, all of 296 metronidazole's action is systemic rather than in the lumen where a reservoir of reproducing 297 and encysting E. histolytica resides. It quite effectively kills invasive trophozoites but allows the 298 parasite's reproductive cycle to continue, enabling the infection of other hosts. To prevent this, 299 metronidazole therapy must be followed by treatment with a luminal antiamoebic drug such as 300 paromomycin, which is potent in that location but not absorbed systemically at all [9, 10] . The 301 current therapeutic strategy thus relies on the sequential administration of two separate drugs 302 each with opposite absorption profiles in order to effectively control both the symptoms and 13 303 spread of amoebiasis. Such a lengthy and complex treatment no doubt greatly aggravates the 304 issues with patient noncompliance described in the first concern. In this study we documented 
343
In conclusion we demonstrated in vitro that the FDA-approved antimalarial drug 344 mefloquine has the potential to act as a new treatment option for E. histolytica infection.
345
Mefloquine is superior to the current practice, due to greater potency, rapidity of action, and 346 cysticidal effects. Further studies using in vivo models of the disease should be undertaken to 347 refine the optimal dosage and duration of treatment. 
